TRUTAKNA cut kidney progression risk 76%. Why did VERA stock give up a double-digit rally?
TRUTAKNA cuts IgA nephropathy progression risk 76% through two years, but VERA stock reverses as competition and launch execution come into focus.
Pharma & Biotech
Pharma & Biotech
Alebund Pharmaceuticals gets FDA IND clearance for AP308 in IgA nephropathy
FDA clears Alebund’s AP308 for human testing in IgA nephropathy, taking a novel IgA-cleaving strategy beyond promising preclinical data.
Pharma & Biotech
Vera Therapeutics has FDA approval for TRUTAKNA, but the real test comes next
Find out how Vera Therapeutics’ TRUTAKNA approval could reshape IgA nephropathy treatment while key kidney data remain ahead.
Pharma & Biotech
Otsuka reports VOYXACT preserved kidney function for two years in Phase 3 trial
Otsuka’s two-year VOYXACT data could reshape IgA nephropathy care. See what the eGFR results mean for FDA approval and clinical adoption.
Pharma & Biotech
How InflaRx N.V. plans to challenge avacopan in ANCA-associated vasculitis with izicopan
InflaRx N.V. is expanding izicopan into renal inflammation and vasculitis markets. Discover what this means for complement inhibitor competition.
Pharma & Biotech
Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.